Reuters: U.S. health regulators have approved Novartis' drug Signifor LAR as a treatment for a rare and life-threatening hormonal disorder, the Swiss drugmaker said on Tuesday.
The Basel-based firm said the U.S. Food and Drug Administration (FDA) backed its drug Signifor LAR to treat acromegaly in adults for whom surgery is not an option, after two late-stage studies showed the drug allowed for greater disease control than existing therapies.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now